Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine for PTSD
NCT02397889Phase 3Completed
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- May 2015
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ketamine in post-traumatic stress disorder (PTSD) (2 arms), sponsored by Icahn School of Medicine at Mount Sinai. Primary endpoint: Clinician-Administered PTSD Scale for DSM-5 at 2 weeks. Started May 2015; status: completed.
02
Drugs
ketamine
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT02397889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02397889.